Therefore, the inhibition of histone acetylation in HepG2 cells to alter the TGF-β signaling pathway may provide targeted therapy for hepatic carcinoma; however, further investigation is required to determine the detailed mechanisms of TGF-β production and activation. Here, TGFB1 is linked to hepatocellular carcinoma.